EMA401 + Placebo

Phase 2Terminated

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Painful Diabetic Neuropathy

Conditions

Painful Diabetic Neuropathy

Trial Timeline

Mar 14, 2018 → Mar 25, 2019

NCT ID

NCT03297294

About EMA401 + Placebo

EMA401 + Placebo is a phase 2 stage product being developed by Novartis for Painful Diabetic Neuropathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT03297294. Target conditions include Painful Diabetic Neuropathy.

What happened to similar drugs?

7 of 20 similar drugs in Painful Diabetic Neuropathy were approved

Approved (7) Terminated (2) Active (11)

✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved

✅Qutenza + PregabalinAstellas PharmaApproved

✅duloxetine hydrochlorideEli LillyApproved

✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved

✅pregabalinPfizerApproved

✅PregabalinPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03297294	Phase 2	Terminated	Mar 14, 2018	Mar 25, 2019	Painful Diabetic Neuropathy
NCT03094195	Phase 2	Terminated	Jun 27, 2017	Mar 7, 2019	Post-herpetic Neuralgia

Competing Products

20 competing products in Painful Diabetic Neuropathy

See all competitors

Product	Company	Stage	Hype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine	Pacira Biosciences	Approved	44
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placebo	Astellas Pharma	Phase 2	27
QUTENZA	Astellas Pharma	Phase 3	40
Qutenza + Pregabalin	Astellas Pharma	Approved	43
duloxetine hydrochloride	Eli Lilly	Approved	43
Duloxetine hydrochloride + placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Phase 3	40
duloxetine hydrochloride + pregabalin + gabapentin	Eli Lilly	Approved	43
Duloxetine + Pregabalin + Placebo	Eli Lilly	Phase 3	40
Placebo + Pregabalin + LY545694 21 mg + LY545694 49 mg + LY545694 105 mg	Eli Lilly	Phase 2	35
GRC 17356 + Matching Placebo	Glenmark Pharmaceuticals	Phase 2	35
GRC 17536 (Medium Dose) + GRC 17536 (Low Dose) + Placebo	Glenmark Pharmaceuticals	Phase 2	27
Tapentadol extended release (ER) + Oxycodone controlled release (CR)	Johnson & Johnson	Phase 3	32
AZD5213 + pregabalin + Placebo + pregabalin capsules	AstraZeneca	Phase 2	35
MEDI7352	AstraZeneca	Phase 2	27
MEDI7352	AstraZeneca	Phase 2	35
MEDI7352 + Placebo	AstraZeneca	Phase 1	29
MK-6096 + Placebo	Merck	Phase 2	35
Comparator: A: Pregabalin + Comparator: B: Duloxetine + Comparator: C: Diphenhydramine hydrochloride	Merck	Phase 2	27
Pregabalin	Pfizer	Phase 3	40